Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regul

"Dear Fellow Shareholders,Over the past several months, our Board of Directors and management te

Up to $50,000,000 Common StockWe have entered into the sales agreement (the "Sales Agreement&#34

PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated

PDS Biotechnology NASDAQ: PDSB reported a smaller first-quarter loss and highlighted changes to its

PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript

PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.13) per share which beat the analys

Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biot

PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS

HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with

PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal can

78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year

78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year

PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript

PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.14) per share which beat the analys

PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late

Full Year 2025 Financial ResultsNet loss for the year ended December 31, 2025, was approximately $34

Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Durat

PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“P

https://www.sec.gov/ix?doc=/Archives/edgar/data/1472091/000114036126007478/ef20067044_8k.htm#fact-id

PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a lat

Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Ca

NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovat

NCI-Led Study Shows Median PFS of 9.6 Months  Results Presented at AACR Special Conference on Innova

PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late

Patent Enhances IP Estate for Lead Asset; Combined with Anticipated Biologics Exclusivity, Market Pr

PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a lat

PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Pro

PDS Biotechnology Corporation (NASDAQ: PDSB - Get Free Report) traded down 1.9% during trading on Tu

New Patent Grants Broad Composition Claims for PDS0101Previously Granted Patent Protections and Anti

New Patent Grants Broad Composition Claims for PDS0101 Previously Granted Patent Protections and Ant

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abo

Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated

B. Riley Securities analyst Kalpit Patel maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and

HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a

PDS Biotechnology Corporation ( PDSB ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company P

PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.19) per share which beat the analys

Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Posi

PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late